The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations
Abstract
Opioid-induced hyperalgesia (OIH) is most broadly defined as a state of nociceptive sensitization caused by exposure to opioids. The state is characterized by a paradoxical response whereby a patient receiving opioids for the treatment of pain may actually become more sensitive to certain painful stimuli. The type of pain experienced may or may not be different from the original underlying painful condition. Although the precise molecular mechanism is not yet understood, it is generally thought to result from neuroplastic changes in the peripheral and central nervous systems that lead to sensitization of pronociceptive pathways. OIH seems to be a distinct, definable, and characteristic phenomenon that may explain loss of opioid efficacy in some cases. Clinicians should suspect expression of OIH when opioid treatment effect seems to wane in the absence of disease progression, particularly if found in the context of unexplained pain reports or diffuse allodynia unassociated with the pain as previously observed. This review highlights the important mechanistic underpinnings and clinical ramifications of OIH and discusses future research directions and the latest clinical evidence for modulation of this potentially troublesome clinical phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications
Khantzian, E. J. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030550 · Cited by 3,242
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.11.1259 · Cited by 2,538
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216
Opioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Self-citationLong-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine
Célèrier, E., Rivat, C., Jun, Y., Laulin, J.-P., Larcher, A., Reynier, P., & Simonnet, G. (2000) · Anesthesiology · doi:10.1097/00000542-200002000-00029 · Cited by 584
Laulin, J.-P., Maurette, P., Corcuff, J.-B., Rivat, C., Chauvin, M., & Simonnet, G. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200205000-00040 · Cited by 344
Célèrier, E., Laulin, J.-P., Corcuff, J.-B., Le Moal, M., & Simonnet, G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-11-04074.2001 · Cited by 315
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent
Compton, P., Charuvastra, V. C., & Ling, W. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00200-3 · Cited by 311
Hyperalgesic responses in methadone maintenance patients
Doverty, M., White, J. M., Somogyi, A. A., Bochner, F., Ali, R., & Ling, W. (2001) · Pain · doi:10.1016/s0304-3959(00)00391-2 · Cited by 297
Research works printed but not linked: 164
- Krjtikos, 1967, The history of poppy and of opium and their expansion in antiquity, Bull Narc, 3, 17
- Gimbel, 2003, Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial, Neurology, 60, 927, 10.1212/01.WNL.0000057720.36503.2C · DOI · Paper page
- Raja, 2002, Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial, Neurology, 59, 1015, 10.1212/WNL.59.7.1015 · DOI · Paper page
- Rowbotham, 2003, Oral opioid therapy for chronic peripheral and central neuropathic pain, N Engl J Med, 348, 1223, 10.1056/NEJMoa021420 · DOI · Paper page
- Watson, 2003, Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy, Pain, 105, 71, 10.1016/S0304-3959(03)00160-X · DOI · Paper page
- Dellemijn, 1997, Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain, Lancet, 349, 753, 10.1016/S0140-6736(96)09024-1 · DOI · Paper page
- Caldwell, 1999, Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial, J Rheumatol, 26, 862
- Roth, 2000, Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation, Arch Intern Med, 160, 853, 10.1001/archinte.160.6.853 · DOI · Paper page
- Moulin, 1996, Randomised trial of oral morphine for chronic non-cancer pain, Lancet, 347, 143, 10.1016/S0140-6736(96)90339-6 · DOI · Paper page
- Arkinstall, 1995, Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial, Pain, 62, 169, 10.1016/0304-3959(94)00262-D · DOI · Paper page
- Katz, 2005, Methodological issues in clinical trials of opioids for chronic pain, Neurology, 65, S32, 10.1212/WNL.65.12_suppl_4.S32 · DOI
- Portenoy, 2007, Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year Registry Study, Clin J Pain, 23, 287, 10.1097/AJP.0b013e31802b582f · DOI · Paper page
- Olsen, 2006, Opioid prescriptions by U.S. primary care physicians from 1992 to 2001, J Pain, 7, 225, 10.1016/j.jpain.2005.11.006 · DOI · Paper page
- Clark, 2002, Chronic pain prevalence and analgesic prescribing in a general medical population, J Pain Symptom Manage, 23, 131, 10.1016/S0885-3924(01)00396-7 · DOI · Paper page
- Rowbotham, 2007, How effective is long-term opioid therapy for chronic noncancer pain?, Clin J Pain, 23, 300, 10.1097/AJP.0b013e318032de5d · DOI
- Mao, 2006, Opioid-induced abnormal pain sensitivity, Curr Pain Headache Rep, 10, 67, 10.1007/s11916-006-0011-5 · DOI
- Ossipov, 2005, Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure, Biopolymers, 80, 319, 10.1002/bip.20254 · DOI · Paper page
- Rossbach, 1880, Ueber die Gewoehnung an Gifte, Pflugers Arch Gesamte Physiol Menschen, 21, 213, 10.1007/BF01637005 · DOI
- Doverty, 2001, Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine, Pain, 93, 155, 10.1016/S0304-3959(01)00306-2 · DOI · Paper page
- Compton, 1994, Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status, J Pain Symptom Manage, 9, 462, 10.1016/0885-3924(94)90203-8 · DOI · Paper page
- Compton, 2000, Pain responses in methadone-maintained opioid abusers, J Pain Symptom Manage, 20, 237, 10.1016/S0885-3924(00)00191-3 · DOI · Paper page
- Dyer, 1999, Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships, Clin Pharmacol Ther, 65, 685, 10.1016/S0009-9236(99)90090-5 · DOI
- Schall, 1996, Pain perception of intravenous heroin users on maintenance therapy with levomethadone, Pharmacopsychiatry, 29, 176, 10.1055/s-2007-979567 · DOI
- Hood, 2003, Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia, Anesth Analg, 97, 810, 10.1213/01.ANE.0000078811.80093.88 · DOI · Paper page
- Angst, 2003, Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal, Pain, 106, 49, 10.1016/S0304-3959(03)00276-8 · DOI · Paper page
- Pud, 2006, Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects, Drug Alcohol Depend, 82, 218, 10.1016/j.drugalcdep.2005.09.007 · DOI
- Martin, 1973, Methadone–a reevaluation, Arch Gen Psychiatry, 28, 286, 10.1001/archpsyc.1973.01750320112017 · DOI · Paper page
- Rainville, 1992, A psychophysical comparison of sensory and affective responses to four modalities of experimental pain, Somatosens Mot Res, 9, 265, 10.3109/08990229209144776 · DOI · Paper page
- Hay, 2003, Clinical evidence for opioid-induced hyperalgesia., Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 10, 4
- Chia, 1999, Intraoperative high dose fentanyl induces postoperative fentanyl tolerance, Can J Anaesth, 46, 872, 10.1007/BF03012978 · DOI · Paper page
- Guignard, 2000, Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement, Anesthesiology, 93, 409, 10.1097/00000542-200008000-00019 · DOI · Paper page
- Cooper, 1997, Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine?, Br J Anaesth, 78, 311, 10.1093/bja/78.3.311 · DOI
- Joly, 2005, Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine, Anesthesiology, 103, 147, 10.1097/00000542-200507000-00022 · DOI · Paper page
- Cortinez, 2001, No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia, Br J Anaesth, 87, 866, 10.1093/bja/87.6.866 · DOI · Paper page
- Lee, 2005, Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide, Anesthesiology, 102, 398, 10.1097/00000542-200502000-00024 · DOI
- Hansen, 2005, Intra-operative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery, Acta Anaesthesiol Scand, 49, 1464, 10.1111/j.1399-6576.2005.00861.x · DOI
- Troster, 2006, Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans, Anesthesiology, 105, 1016, 10.1097/00000542-200611000-00024 · DOI
- Koppert, 2001, A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine, Anesthesiology, 95, 395, 10.1097/00000542-200108000-00022 · DOI · Paper page
- Koppert, 2003, Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans, Anesthesiology, 99, 152, 10.1097/00000542-200307000-00025 · DOI · Paper page
- Luginbuhl, 2003, Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans, Anesth Analg, 96, 726, 10.1213/01.ANE.0000048086.58161.18 · DOI
- Compton, 2004, Precipitated opioid withdrawal across acute physical dependence induction methods, Pharmacol Biochem Behav, 77, 263, 10.1016/j.pbb.2003.10.017 · DOI
- Chu, 2006, Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study, J Pain, 7, 43, 10.1016/j.jpain.2005.08.001 · DOI · Paper page
- Aley, 1995, Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal, J Neurosci, 15, 8031, 10.1523/JNEUROSCI.15-12-08031.1995 · DOI
- Aley, 1997, Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat, J Neurosci, 17, 8018, 10.1523/JNEUROSCI.17-20-08018.1997 · DOI
- Aley, 1997, Dissociation of tolerance and dependence for opioid peripheral antinociception in rats, J Neurosci, 17, 3907, 10.1523/JNEUROSCI.17-10-03907.1997 · DOI
- Aley, 1997, Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal, J Neurosci, 17, 735, 10.1523/JNEUROSCI.17-02-00735.1997 · DOI · Paper page
- Arts, 1991, Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala2-Gly-NMePhe4-Gly-ol5 (DAMGO) and morphine-induced antinociception in mice, J Pharmacol Exp Ther, 256, 890
- Liang, 2006, A genetic analysis of opioid-induced hyperalgesia in mice, Anesthesiology, 104, 1054, 10.1097/00000542-200605000-00023 · DOI
- Mao, 1994, Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C, J Neurosci, 14, 2301, 10.1523/JNEUROSCI.14-04-02301.1994 · DOI · Paper page
- Dunbar, 1998, Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat, J Pharmacol Exp Ther, 284, 678, 10.1016/S0022-3565(24)37250-7 · DOI
- Rivat, 2002, Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine, Anesthesiology, 96, 381, 10.1097/00000542-200202000-00025 · DOI · Paper page
- Li, 2001, A murine model of opioid-induced hyperalgesia, Brain Res Mol Brain Res, 86, 56, 10.1016/S0169-328X(00)00260-6 · DOI
- Sweitzer, 2004, Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C epsilon and gamma, Pain, 110, 281, 10.1016/j.pain.2004.04.004 · DOI
- Vanderah, 2000, Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance, J Neurosci, 20, 7074, 10.1523/JNEUROSCI.20-18-07074.2000 · DOI · Paper page
- Dunbar, 2000, The effect of spinal ibuprofen on opioid withdrawal in the rat, Anesth Analg, 91, 417
- Johnston, 2004, A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine, J Neurosci, 24, 7353, 10.1523/JNEUROSCI.1850-04.2004 · DOI · Paper page
- Vera-Portocarrero, 2007, Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways, Pain, 129, 35, 10.1016/j.pain.2006.09.033 · DOI
- Li, 2002, Hyperalgesia during opioid abstinence: mediation by glutamate and substance p, Anesth Analg, 95, 979, 10.1213/00000539-200210000-00035 · doi:10.1213/00000539-200210000-00035
- Belanger, 2002, Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates, Neuroscience, 115, 441, 10.1016/S0306-4522(02)00452-9 · DOI
- Mao, 2002, Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity, J Neurosci, 22, 8312, 10.1523/JNEUROSCI.22-18-08312.2002 · DOI · Paper page
- Ossipov, 2004, Antinociceptive and nociceptive actions of opioids, J Neurobiol, 61, 126, 10.1002/neu.20091 · DOI · Paper page
- Vanderah, 2001, Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance, J Neurosci, 21, 279, 10.1523/JNEUROSCI.21-01-00279.2001 · DOI · Paper page
- Xie, 2005, Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance, J Neurosci, 25, 409, 10.1523/JNEUROSCI.4054-04.2005 · DOI · Paper page
- Liang, 2006, Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence, Pharmacogenet Genomics, 16, 825, 10.1097/01.fpc.0000236321.94271.f8 · DOI
- Schinkel, 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J Clin Invest, 96, 1698, 10.1172/JCI118214 · DOI · Paper page
- Andrews, 1943, The effect of opiates on the pain threshold in post-addicts, J Clin Invest, 22, 511, 10.1172/JCI101420 · DOI
- Joshi, 1999, Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia, Anesthesiology, 90, 1007, 10.1097/00000542-199904000-00013 · DOI
- Gan, 1997, Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate, Anesthesiology, 87, 1075, 10.1097/00000542-199711000-00011 · DOI · Paper page
- Cepeda, 2002, The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period, Pain, 96, 73, 10.1016/S0304-3959(01)00425-0 · DOI
- Cepeda, 2004, Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects, Pain, 107, 41, 10.1016/j.pain.2003.09.011 · DOI
- Kayser, 1987, Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats), Brain Res, 414, 155, 10.1016/0006-8993(87)91338-2 · DOI
- Shen, 1994, Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence, Brain Res, 636, 286, 10.1016/0006-8993(94)91028-6 · DOI
- Kayser, 1981, Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats, Brain Res, 226, 344, 10.1016/0006-8993(81)91110-0 · DOI
- Woolf, 1980, Analgesia and hyperalgesia produced in the rat by intrathecal naloxone, Brain Res, 189, 593, 10.1016/0006-8993(80)90375-3 · DOI
- Smith, 2000, Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites, Clin Exp Pharmacol Physiol, 27, 524, 10.1046/j.1440-1681.2000.03290.x · DOI · Paper page
- Wright, 2001, Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide, Life Sci, 69, 409, 10.1016/S0024-3205(01)01133-X · DOI
- Sjogren, 1993, Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine, Pain, 55, 93, 10.1016/0304-3959(93)90188-U · DOI
- Sjogren, 1994, Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists, Pain, 59, 313, 10.1016/0304-3959(94)90084-1 · DOI · Paper page
- Wilson, 2003, Morphine hyperalgesia: a case report, Am J Hosp Palliat Care, 20, 459, 10.1177/104990910302000608 · DOI
- De Conno, 1991, Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine, Pain, 47, 337, 10.1016/0304-3959(91)90225-M · DOI · Paper page
- Lawlor, 1997, Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study, Pain, 72, 79, 10.1016/S0304-3959(97)00018-3 · doi:10.1016/s0304-3959(97)00018-3
- Sjogren, 1998, Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories, Acta Anaesthesiol Scand, 42, 1070, 10.1111/j.1399-6576.1998.tb05378.x · DOI
- Heger, 1999, Morphine induced allodynia in a child with brain tumour, BMJ, 319, 627, 10.1136/bmj.319.7210.627 · DOI
- Lawlor, 1997, Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence, J Pain Symptom Manage, 13, 356, 10.1016/S0885-3924(97)00081-X · DOI
- Parisod, 2003, Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury, Anesth Analg, 97, 183, 10.1213/01.ANE.0000068482.67289.1A · DOI
- Mercadante, 2003, Hyperalgesia: an emerging iatrogenic syndrome, J Pain Symptom Manage, 26, 769, 10.1016/S0885-3924(03)00258-6 · DOI
- Devulder, 1997, Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain, J Neurosurg Anesthesiol, 9, 146, 10.1097/00008506-199704000-00007 · DOI
- Mercadante, 2005, Hyperalgesia and opioid switching, Am J Hosp Palliat Care, 22, 291, 10.1177/104990910502200411 · DOI
- Guntz, 2007, Opioid-induced hyperalgesia, Eur J Anaesthesiol, 24, 205, 10.1017/S0265021506001700 · DOI
- Axelrod, 2007, Using methadone to treat opioid-induced hyperalgesia and refractory pain, J Opioid Manag, 3, 113, 10.5055/jom.2007.0048 · DOI
- Ackerman, 2006, Paroxysmal opioid-induced pain and hyperalgesia, J Ky Med Assoc, 104, 419
- Chung, 2004, Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia, Conn Med, 68, 547
- Woolf, 1981, Intrathecal high dose morphine produces hyperalgesia in the rat, Brain Res, 209, 491, 10.1016/0006-8993(81)90176-1 · DOI · Paper page
- Yaksh, 1988, Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine, J Pharmacol Exp Ther, 244, 501
- Yaksh, 1986, High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications, Anesthesiology, 64, 590, 10.1097/00000542-198605000-00008 · DOI · Paper page
- Sakurada, 2002, Intrathecal high-dose morphine induces spinally-mediated behavioral responses through NMDA receptors, Brain Res Mol Brain Res, 98, 111, 10.1016/S0169-328X(01)00332-1 · DOI
- Hara, 1997, Characterization of nociceptin hyperalgesia and allodynia in conscious mice, Br J Pharmacol, 121, 401, 10.1038/sj.bjp.0701146 · DOI
- Dudgeon, 2007, A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients, J Pain Symptom Manage, 33, 365, 10.1016/j.jpainsymman.2006.09.017 · DOI
- Galer, 2005, MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance, Pain, 115, 284, 10.1016/j.pain.2005.03.004 · DOI
- Orser, 1995, Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones, Br J Pharmacol, 116, 1761, 10.1111/j.1476-5381.1995.tb16660.x · DOI · Paper page
- Grasshoff, 2005, Effects of propofol on N-methyl-D-aspartate receptor-mediated calcium increase in cultured rat cerebrocortical neurons, Eur J Anaesthesiol, 22, 467, 10.1017/S0265021505000803 · DOI
- Kingston, 2006, Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons, Anesthesiology, 104, 763, 10.1097/00000542-200604000-00021 · DOI
- Chen, 2006, The chemical biology of clinically tolerated NMDA receptor antagonists, J Neurochem, 97, 1611, 10.1111/j.1471-4159.2006.03991.x · DOI · Paper page
- Snijdelaar, 2004, Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study, Anesthesiology, 100, 134, 10.1097/00000542-200401000-00022 · doi:10.1097/00000542-200401000-00022
- Sang, 2000, NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials, J Pain Symptom Manage, 19, S21, 10.1016/S0885-3924(99)00125-6 · DOI
- Mathiesen, 2006, CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model, J Pain, 7, 565, 10.1016/j.jpain.2006.02.004 · DOI
- Bassani, 2005, CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats, Eur J Pharmacol, 519, 231, 10.1016/j.ejphar.2005.07.004 · DOI
- Astruc, 2005, Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects, Br J Clin Pharmacol, 59, 405, 10.1111/j.1365-2125.2005.02338.x · DOI
- Heiskanen, 2002, Analgesic effects of dextromethorphan and morphine in patients with chronic pain, Pain, 96, 261, 10.1016/S0304-3959(01)00455-9 · DOI
- Tverskoy, 1994, Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia, Anesth Analg, 78, 205, 10.1213/00000539-199402000-00002 · DOI · Paper page
- Bell, 1999, Low-dose subcutaneous ketamine infusion and morphine tolerance, Pain, 83, 101, 10.1016/S0304-3959(99)00096-2 · DOI
- De Kock, 2001, “Balanced analgesia” in the perioperative period: is there a place for ketamine?, Pain, 92, 373, 10.1016/S0304-3959(01)00278-0 · DOI · Paper page
- Ilkjaer, 1996, Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans, Br J Anaesth, 76, 829, 10.1093/bja/76.6.829 · DOI
- Klein, 2008, Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia, Eur J Pain, 12, 17, 10.1016/j.ejpain.2007.02.002 · DOI
- Rammes, 2006, Neramexane (merz pharmaceuticals/forest laboratories), IDrugs, 9, 128
- Thisted, 2006, Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study, Clin Ther, 28, 1607, 10.1016/j.clinthera.2006.10.005 · DOI
- Williams, 2001, Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action, Curr Drug Targets, 2, 285, 10.2174/1389450013348489 · DOI
- Boyce, 1999, Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn, Neuropharmacology, 38, 611, 10.1016/S0028-3908(98)00218-4 · DOI · Paper page
- Taniguchi, 1997, Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist, Br J Pharmacol, 122, 809, 10.1038/sj.bjp.0701445 · DOI
- Goebel, 1999, NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A, Brain Res Mol Brain Res, 69, 164, 10.1016/S0169-328X(99)00100-X · DOI · Paper page
- Zukin, 1995, Alternatively spliced isoforms of the NMDARI receptor subunit, Trends Neurosci, 18, 306, 10.1016/0166-2236(95)93920-S · DOI · Paper page
- White, 1996, Pharmacological properties of ketamine, Drug Alcohol Rev, 15, 145, 10.1080/09595239600185801 · DOI
- Reich, 1989, Ketamine: an update on the first twenty-five years of clinical experience, Can J Anaesth, 36, 186, 10.1007/BF03011442 · DOI · Paper page
- Annetta, 2005, Ketamine: new indications for an old drug, Curr Drug Targets, 6, 789, 10.2174/138945005774574533 · DOI
- Sloan, 2002, Anesthetics and the brain, Anesthesiol Clin North America, 20, 265, 10.1016/S0889-8537(01)00002-5 · DOI
- Elia, 2005, Ketamine and postoperative pain–a quantitative systematic review of randomised trials, Pain, 113, 61, 10.1016/j.pain.2004.09.036 · DOI · Paper page
- Bell, 2006, Perioperative ketamine for acute postoperative pain, Cochrane Database Syst Rev, CD004603
- Stubhaug, 1997, Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery, Acta Anaesthesiol Scand, 41, 1124, 10.1111/j.1399-6576.1997.tb04854.x · DOI · Paper page
- Bell, 2003, Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review, J Pain Symptom Manage, 26, 867, 10.1016/S0885-3924(03)00311-7 · DOI
- Eilers, 2001, The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine, Anesth Analg, 93, 213, 10.1097/00000539-200107000-00042 · DOI
- Zimmermann, 2005, Rotation to methadone after opioid dose escalation: how should individualization of dosing occur?, J Pain Palliat Care Pharmacother, 19, 25
- Bowsher, 1993, Paradoxical pain, BMJ, 306, 473, 10.1136/bmj.306.6876.473 · doi:10.1136/bmj.306.6876.473
- Skarke, 2005, Is morphine-3-glucuronide of therapeutic relevance?, Pain, 116, 177, 10.1016/j.pain.2005.06.006 · doi:10.1016/j.pain.2005.06.006
- Katz, 2000, MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients, J Pain Symptom Manage, 19, S37, 10.1016/S0885-3924(99)00129-3 · DOI
- Caruso, 2000, MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain, J Pain Symptom Manage, 19, S31, 10.1016/S0885-3924(99)00128-1 · doi:10.1016/s0885-3924(99)00128-1
- Chevlen, 2000, Morphine with dextromethorphan: conversion from other opioid analgesics, J Pain Symptom Manage, 19, S42, 10.1016/S0885-3924(99)00130-X · DOI
- Lipton, 1994, Excitatory amino acids as a final common pathway for neurologic disorders, N Engl J Med, 330, 613, 10.1056/NEJM199403033300907 · DOI · Paper page
- Rang, 1981, Drugs and ionic channels: mechanisms and implications, Postgrad Med J, 57, 89
- Chen, 1992, Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity, J Neurosci, 12, 4427, 10.1523/JNEUROSCI.12-11-04427.1992 · DOI · Paper page
- Chen, 1997, Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism, J Physiol, 499, 27, 10.1113/jphysiol.1997.sp021909 · DOI · Paper page
- Lipton, 1993, Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide, Trends Neurosci, 16, 527, 10.1016/0166-2236(93)90198-U · DOI · Paper page
- Chen, 1998, Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation, Neuroscience, 86, 1121, 10.1016/S0306-4522(98)00163-8 · DOI · Paper page
- Ditzler, 1991, Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial, Arzneimittelforschung, 41, 773
- Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 · DOI · Paper page
- Reisberg, 2006, A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease, Arch Neurol, 63, 49, 10.1001/archneur.63.1.49 · DOI · Paper page
- Eisenberg, 1995, The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy, Neurosci Lett, 187, 17, 10.1016/0304-3940(95)11326-R · DOI
- Carlton, 1995, Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats, Neurosci Lett, 198, 115, 10.1016/0304-3940(95)11980-B · DOI
- Chaplan, 1997, Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat, J Pharmacol Exp Ther, 280, 829, 10.1016/S0022-3565(24)36427-4 · DOI · Paper page
- Sinis, 2007, Memantine treatment of complex regional pain syndrome: a preliminary report of six cases, Clin J Pain, 23, 237, 10.1097/AJP.0b013e31802f67a7 · DOI
- Schifitto, 2006, A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy, J Neurovirol, 12, 328, 10.1080/13550280600873835 · DOI
- Sang, 2002, Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials, Anesthesiology, 96, 1053, 10.1097/00000542-200205000-00005 · DOI · Paper page
- Eisenberg, 1998, The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study, Eur J Pain, 2, 321, 10.1016/S1090-3801(98)90030-1 · DOI
- Nikolajsen, 2000, Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study, Anesth Analg, 91, 960, 10.1097/00000539-200010000-00036 · DOI · Paper page
- Chizh, 2001, NMDA receptor antagonists as analgesics: focus on the NR2B subtype, Trends Pharmacol Sci, 22, 636, 10.1016/S0165-6147(00)01863-0 · DOI · Paper page
- Ma, 2000, Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats, Neuroscience, 101, 699, 10.1016/S0306-4522(00)00419-X · DOI
- Wang, 2004, GABAA receptor partially mediated propofol-induced hyperalgesia at superspinal level and analgesia at spinal cord level in rats, Acta Pharmacol Sin, 25, 1619
- Baba, 2001, Direct activation of rat spinal dorsal horn neurons by prostaglandin E2, J Neurosci, 21, 1750, 10.1523/JNEUROSCI.21-05-01750.2001 · DOI · Paper page
- O'Rielly, 2006, Increased expression of cyclooxygenase and nitric oxide isoforms, and exaggerated sensitivity to prostaglandin E2, in the rat lumbar spinal cord 3 days after L5-L6 spinal nerve ligation, Anesthesiology, 104, 328, 10.1097/00000542-200602000-00019 · DOI
- Malmberg, 1992, Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition, Science, 257, 1276, 10.1126/science.1381521 · DOI · Paper page
- Yaksh, 1993, Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products, Agents Actions Suppl, 41, 89
- Powell, 1999, Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance, Br J Pharmacol, 127, 631, 10.1038/sj.bjp.0702587 · DOI
- Wong, 2000, Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats, Br J Anaesth, 85, 747, 10.1093/bja/85.5.747 · DOI
- Quartilho, 2004, Production of paradoxical sensory hypersensitivity by alpha 2-adrenoreceptor agonists, Anesthesiology, 100, 1538, 10.1097/00000542-200406000-00029 · DOI
- Miaskowski, 2002, Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control, J Pain, 3, 12, 10.1054/jpai.2002.27002 · DOI
Cited by
A Comprehensive Review of Opioid-Induced Hyperalgesia
Lee, M. O. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/145 · Cited by 1,118
Overtreating chronic back pain: time to back off?
Deyo, R. A., Mirza, S. K., Turner, J. A., & Martin, B. I. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.01.080102 · Cited by 796
Treatment of chronic non-cancer pain
Turk, D. C., Wilson, H. D., & Cahana, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60402-9 · Cited by 716
Treatment of acute postoperative pain
Wu, C. L., & Raja, S. N. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60245-6 · Cited by 628
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Metadata
- Authors
- Chu, L. F., Angst, M. S., & Clark, D.
- Venue
- The Clinical Journal of Pain
- Published
- 2008-07
- Volume
- 24
- Issue
- 6
- Pages
- 479-496
- ISSN
- 0749-8047 (ISSN-L)
- OpenAlex
- W2024836296
- Cited by
- 575
- References
- 16
- FWCI
- 38.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. https://app.cochat.ai/papers/10.1097/ajp.0b013e31816b2f43
- The paper
- Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. The Clinical Journal of Pain. https://doi.org/10.1097/ajp.0b013e31816b2f43
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.